

2019年昆明国际肿瘤研究论坛

2019 International Cancer Symposium in Kunming

会议手册



主办单位

中国科学院昆明动物研究所

昆明医科大学第三附属医院（云南省肿瘤医院）

协办单位

中国细胞生物学学会肿瘤细胞生物学分会

珀金埃尔默企业管理（上海）有限公司

2019年7月24日


云南·昆明

欢迎词

盛夏七月，时值**2019**昆明国际肿瘤研究论坛在昆明隆重召开，中国科学院昆明动物研究所、昆明医科大学第三附属医院（云南省肿瘤医院）、中国细胞生物学学会肿瘤细胞学分会和珀金埃尔默企业管理（上海）有限公司联合主办本次会议。

届时，来自国内外癌症研究领域的著名专家学者们将齐聚一堂，围绕“癌症基础研究和临床治疗”的主题进行深入的探讨。近年来，癌症发病率日益增加，防治工作任重道远。本届会议邀请了国内外癌症研究领域顶尖的华人学者和我们共同分享与探讨癌症发生、发展和治疗的新知识和远见。

我们谨代表主办方，热忱欢迎大家来昆明参加本次会议，预祝会议取得圆满成功！



组委会

中科院昆明动物所：陈策实、陈勇彬

云南省肿瘤医院：李文辉、杨宏英

中国细胞生物学学会肿瘤细胞学分会：王平、焦保卫

珀金埃尔默企业管理（上海）有限公司：汪晓刚

会议须知

地点：恒盛酒店二楼，恒盛厅

（昆明市龙泉路77号，0871-68211257）

秘书：

孔燕杰、王霜（中科院昆明动物所）

常莉、李政（云南省肿瘤医院）

赵枝归（珀金埃尔默企业管理（上海）有限公司）

联系方式：kongyanjie26@163.com

住宿安排：

外单位嘉宾统一入住恒盛酒店

从龙泉路步行至昆明动物研究所

全程约5分钟





出席嘉宾

- 黄云超 云南省肿瘤医院
- 李文辉 云南省肿瘤医院
- 杨宏英 云南省肿瘤医院
- 陈勇彬 中科院昆明动物研究所
- 焦保卫 中科院昆明动物研究所
- 李堯生 Cell Res 执行主编
- 曾木圣 中山大学肿瘤防治中心
- 康铁邦 中山大学肿瘤防治中心
- 贾立军 上海中医药大学
- 郭彩霞 中科院基因组研究所
- 刘文 厦门大学
- 冯海忠 上海交通大学医学院附属仁济医院
- 蒋德伟 中科院昆明动物研究所
- 刘蓉 中科院昆明动物研究所
- 陈文林 肿瘤医院
- 余敏 云南大学
- 唐慧 云南省第一人民医院
- 邹云莲 云南省第一人民医院
- 侯宗柳 昆明市延安医院中心实验室
- 王文举 昆明市延安医院中心实验室
- 李琳 昆明市延安医院中心实验室

会议日程

7月24日	报告题目	报告人	单位	主持人
8:30-09:00	开幕式 (集体合影)			陈策实
9:00-9:30	Marker-guided target therapy, PAPR and EGFR inhibitors, and development of effective immune checkpoint therapy	Mien-Chie Hung 洪明奇	China Medical University in Taichung / MD Anderson Cancer Center	康铁邦 刘文
9:30-10:00	Regulation of Osteoblasts by Breast Cancer-secreted miR-218	Emily Wang 王世珍	University of California San Diego	
10:00-10:30	SIRT2, a tumor suppressor or promoter?	Feng Xia 夏芬	University of Arkansas for Medical Science	
10:30-10:40	茶歇			
10:40-11:10	Editing the Mouse Genome for Understanding the Mechanisms of Cancer Initiation, Progression and Metastasis	Jian-Ming Xu 徐建明	Baylor College of Medicine	贾立军 郭彩霞
11:10-11:40	Liver cancer, from mechanism to combo immunotherapy	Gen-Sheng Feng 冯根生	University of California San Diego	
11:40-12:10	Decoding Brain Metastasis and Devising Effective Therapies	Di-Hua Yu 余揀华	MD Anderson Cancer Center	
12:10-13:30	午餐			
13:30-14:00	CRL3/SPOP promotes Nanog destruction to suppress stem cell traits and prostate cancer progression	Wen-Yi Wei 魏文毅	Harvard Medical School	李亮生
14:00-14:30	The interaction of circular RNAs with proteins	Burton B Yang 杨柏华	University of Toronto	
14:30-15:00	Genomics and Bioinformatics Approaches to Target Discoveries in Prostate Cancer	Jin-Dan Yu 俞锦丹	Northwestern University Feinberg School of Medicine	杨宏英
15:00-15:30	Improving targeted therapy of EGFR mutant NSCLC with third generation EGFR inhibitors	Shi-Yong Sun 孙士勇	Emory University	
15:30-15:50	Every cancer tells a story if you have the tools to read it .PerkinElmer integrated innovative solution for cancer therapy	Amy 张薇	珀金埃尔默企业管理(上海)有限公司	
15:50-16:00	茶歇			
16:00-16:30	Pregnancy, Lactation, and Breast Cancer risk—A Mechanistic Insight	Yi Li 李毅	Baylor College of Medicine	焦保卫
16:30-17:00	Ubiquitin signaling and the DNA damage response	Zhen-Kun Lou 楼振昆	Mayo Clinic	陈勇彬
17:00-17:30	Confounding roles of BCCIP, an essential caretaker gene, in tumor suppression and progression	Zhi-Yuan Shen 沈智渊	Rutgers, The State University of New Jersey	李文辉
17:30-18:00	Cancer Patient Derived Organoid for Precision Oncology	Chu-Xia Deng 邓初夏	University of Macau	冯海忠
18:00-18:10	闭幕式			
18:00	晚餐			

演讲专家介绍 (按报告先后排序)



Mien-Chie Hung
洪明奇
China Medical
University in Taichung
/ MD Anderson Cancer
Center

Mien-Chie Hung, Ph.D. is the President for China Medical University in Taichung, Taiwan. He was vice president for basic research and professor and chair of the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center. He received undergraduate and graduate degrees from the National Taiwan University and his PhD from Brandeis University. After completing postdoctoral training with Dr. Robert A. Weinberg at the Whitehead Institute/Massachusetts Institute of Technology. Dr. Hung was recruited to MD Anderson in 1986. Dr. Hung is internationally recognized for his studies of signal transduction pathways regulated by tyrosine kinase growth factor receptors, such as EGFR and HER-2/neu, as well as molecular mechanisms of tumorigenesis. Up to date, Dr. Hung has published more than 525 peer-reviewed articles, of which over 130 were published in journals with impact factor 10 or above. His lifetime h-index surpasses 110. Dr. Hung has served in many study sections of the NIH and various funding agencies in many other countries to select awardees. He is one of members of Selection Committee for Tang Prize in Biopharmaceutical Science category and 2016 Pezcoller Foundation-AACR Award.

Dr. Hung also serves as an editorial member for many journals in cancer research to evaluate quality of submission. Notable, he is one of the founding Editorial Members for Cancer Cell, serves as Editor-in-chief for American Journal for Cancer Research (2015-2017) and Senior Editor for Cancer Research (American Association for Cancer Research, 2018-2021). Dr. Hung was inducted as an Academician of the Academia Sinica in Taiwan in 2002. In addition, Dr. Hung was selected as a Fellow in Biological Sciences section, American Association for the Advancement of Science (AAAS Fellow) in 2010. He served as President for the Society of Chinese Bioscientists in America (SCBA) from 2004-2005 and is also the recipient of SCBA's Presidential Award in 2011 and Lifetime Achievement Award in 2017. In addition, Dr. Hung was awarded with The University of Texas MD Anderson Cancer Center LeMaistre Outstanding Achievement Award in 2011 as well as Faculty Achievement Award in Education (1993) and in Basic Research (1998 & 2017). In 2015, he was an awardee of the Simiao Sun Award for Biomedical Achievement, and an inaugural awardee of Breast Cancer Basic and Translational Research Outstanding Achievement Award in 2017 International Breast Cancer Stem Cell Symposium.

In 2018, he becomes the President-elect of The University of Texas Academy of Health Science Education. It is worth noting that Dr. Hung is a dedicated educator who persistently nurture next generation cancer biologists. In addition to graduating more than 55 Ph.D. students and directly supervising close to 200 postgraduate fellows, he is a recipient of prestigious educational awards including 2017 UT System Regents' Outstanding Teaching Award and John P. McGovern Outstanding Teacher Award University of Texas Health Science Center-Houston. Dr. Hung is the only faculty who receives the latter award four times.

Dr. Hung is a basic scientist with a keen translational vision and especially his recent research effort has significantly contributed to understanding the biology of cancer and to developing combinational cancer therapies to overcome resistance. His laboratory has a long term commitment to the following research areas: 1) discovery of novel functionality of epidermal growth factor receptor (EGFR) family which may provide useful insight to understand cancer formation and development; 2) identification of crosstalks of signal pathways/networks in cancer cells and tumor microenvironment which could potentially predict resistance to target therapy; 3) development of marker-guided targeted therapy including PARP and EGFR inhibitors, immune checkpoint therapy which will effectively treat cancer patients.



Emily Wang
王世珍
University of California
San Diego

S. Emily Wang, Ph.D., is currently an Associate Professor of Pathology at the University of California, San Diego. She first began her research career in the late 1990s as a virologist and obtained her doctorate from the University of Nebraska-Lincoln and Nankai University, followed by post-doctoral training at the Johns Hopkins University and Vanderbilt University. Before joining UCSD in 2016, Dr. Wang was an Assistant/Associate Professor of Cancer Biology at the Beckman Research Institute of the City of Hope. Dr. Wang is the recipient of a NIH K99/R00 Pathway to Independence Award and several R01 grants. She has also received several IDEA awards from the California Breast Cancer Research Program and an AACR-Breast Cancer Research Foundation translational award. Dr. Wang has more than 60 publications related to her research in cancer and viral oncology, including several recent publications related to extracellular miRNAs in *Nature Cell Biology*, *Cancer Cell*, and *Cell Metabolism*, etc. Her lab is currently exploring additional mechanisms through which cancer-derived extracellular miRNAs contribute to the multifaceted reprogramming of non-cancerous cells in the tumor microenvironment as well as novel therapeutic strategies targeting cancer-derived extracellular miRNAs for their function in cancer-host communication.



Jian-Ming Xu
徐建明
Baylor College of Medicine

Dr. Jian-Ming Xu obtained his PhD degree from Clarkson University in USA, and accomplished his postdoctoral research training programs in Texas A&M University and Baylor College of Medicine. Dr. Xu has been a faculty member in the Department of Molecular and Cellular Biology (MCB) at Baylor College of Medicine since 1997. He currently holds a tenured full professor position in the Department of Molecular and Cellular Biology and the Director position in the Genetically Engineered Mouse Core Laboratory at Baylor College of Medicine. Right after the nuclear receptor coactivator (SRC) family genes were identified in 1990s, Dr. Xu was the first who carried out the initial studies that defined the physiological function of these nuclear receptor coactivators and their roles in mammary gland and prostate tumorigenesis by using knockout mouse models. Dr. Xu's current research interest is focused on understanding the roles and molecular mechanisms of selected transcription factors such as nuclear receptors, Twist, TCF4, and NFY and selected transcriptional coregulators such as SRC-1, SRC-3 and NCOA6 in steroid hormone-promoted cancers, including breast, prostate and endometrial cancers. Dr. Xu has published more than 180 peer-reviewed articles in scientific journals such as *Science*, *Nature*, *Cancer cell*, *Molecular Cell*, *Developmental Cell*, *Cell Metabolism*, *Circulation*, *Nature Cell Biology*, *Nature Reviews Cancer*, *PNAS*, *Cancer Research*, *Oncogene*, *Breast Cancer Research*, *Cell Research*, *Molecular and Cellular Biology*, *Journal of Biological Chemistry*, *Endocrinology and Molecular Endocrinology*, etc.



Fen Xia
夏芬
University Arkansas for
Medical Science

Fen Xia, Professor and Chairman of Radiation Oncology Department, University Arkansas for Medical Science.

Education: PhD, Cancer Biology, Harvard University, Boston, Massachusetts, USA
MD, Suzhou Medical College, Suzhou, China

Other Positions: Chairman, Department of Radiation Oncology, University Arkansas for Medical Science

Clinical interests: Radiation oncologist specializing in tumors of central nerve system

Research Interests: DNA damage response, carcinogenesis, host and tumor response to cancer therapy

Representative Publications:

- Yang ES, Wang H, Hallahan DE, and Xia F. Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent nonhomologous end joining of chromosomal breaks. *J. Clin Invest* 119(5):1124-35, 2009
- Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, Haffty B, Xia F. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. *Cancer Res* 15; 71(16):5546-5557. 2011
- Jiang G, Plo I, Wang T, Rahman M, Cho JH, Yang E, Lopez BS, Xia F. BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal double-strand breaks in the G1 phase of the cell cycle. *J Biol Chem* 2013 Mar 29;288(13):8966-76.
- ST. Sizemore, H. Yu, R. Mohammad, GM. Sizemore, S. Nowsheen, MC. Ostrowski, A. Chakravarti, and F. Xia, Ionizing radiation-induced synthetic lethality of PARP inhibition in BRCA1-proficient cancer cells depends on p53, *Molecular Cancer Therapy*, 2018
- K. Arneson, J. Mondschein, M. Stavas, AJ. Cmelak, L. Horn, K. Niermann, I. Puzanov, B. Chakravarthy, F. Xia, A phase I study of concurrent Sorafenib and stereotactic radiosurgery for patients with brain metastasis, *Journal of Neuro-Oncology* (2017) 133:435-442
- ST. Sizemore, M. Zhang, JH. Cho, GM. Sizemore, B. Hurwitz, B. K. NL. Lehman, MC. Ostrowski, PA. Robe, A. Chakravarti, and F. Xia, Pyruvate kinase M2 promotes DNA repair and cancer resistance to genotoxic therapies, accepted in *Cell Research*, (2018) 28(11):1090-1102



Di-Hua Yu
余稼华
MD Anderson Cancer
Center

Di-Hua Yu is a Professor and the Chair ad interim of the Department of Molecular and Cellular Oncology, and the Hubert L. & Olive Stringer Distinguished Chair in Basic Science at The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA. Dr. Yu received her Bachelor of Medicine degree in 1982 and completed Master of Science study in 1985 from the Capital University of Medicine in Beijing, and received her Ph.D. degree in Molecular Biology and Cancer Biology from the Graduate School of Biomedical Sciences, Univ. Texas Health Science Center-Houston in 1991. She is also co-director of the Preclinical and Translational Brain Metastasis Research Program, co-director of the CCSG Program on Cancer Biology and Metastasis, and director of the Functional Genomics Core of the MDACC.

Dr. Yu's innovative translational research on molecular mechanisms of breast cancer initiation, progression, metastasis and therapeutic resistance has led to several successful multi-center phase I/II clinical trials. Over the past three decades, she has performed high impact research and published almost 200 papers (h-Index 65), including papers in *Nature*, *Nature Medicine*, *Nature Cell Biology*, *Cell*, *Cancer Cell*, *Molecular Cell*, *JCO.*, *JNCI*, *Cell Res.* etc.


Dr. Yu's achievements have been recognized by the scientific community. She now serves as the President of the Metastasis Research Society (MRS) (8/2018-11/2020) and the Editor-in-Chief of the *American Journal of Cancer Research*. She was elected a Fellow of American Association for the Advancement of Science (AAAS) in 2011. She received the UT System Regents' Outstanding Teaching Award, MD Anderson Faculty Achievement Award in Basic Research, MD Anderson Distinguished Faculty Research Mentor Award in 2012, and she was awarded in 2014 the Sowell-Huggins Professorship in Cancer Research by the UT Graduate School of Biomedical Sciences. She was elected the President (2014-2015) of Society of Chinese Bio-scientists in America (SCBA) which consists of approximately 3,000 members of bio-scientists worldwide. She has also been honored with the 2016 I. J. Fidler Innovator Award in Metastasis Research by the MRS, and the Impact Award by the Society of Breast Cancer in Taiwan.



Gen-Sheng Feng
冯根生
University of California
San Diego

Gen-Sheng Feng, Ph.D. is a Professor of Pathology and Molecular Biology at the University of California San Diego (UCSD). Dr. Feng's research program is centered on dissecting the anti-oncogenic effects of pro-oncogenic proteins in the liver recently identified by his group and others. His most recent findings may lead to development of a preventive strategy for liver cancer in a huge population of patients with chronic liver diseases, and an effective combination immunotherapy for advanced liver cancer patients by coordinated activation of innate and adaptive immunity.

Dr. Feng received Ph.D. degree from Indiana University Bloomington, and did postdoctoral work with Dr. Bryan Williams at the Hospital for Sick Children, and with Tony Pawson at the Mt Sinai Hospital in Toronto, Canada. Dr. Feng has published 172 peer-reviewed research papers, reviews and book chapters in Science, Nature Medicine, Cancer Cell, PNAS, Immunity, Nature Immunology, Genes & Deve, MCB, JBC. Blood, Hepatology, J Hepatology and J. Immunol, etc. Dr. Feng has served on the editorial boards of Molecular and Cellular Biology (MCB), Journal of Biological Chemistry (JBC), Hepatology, and Journal of Hepatology. In 2016, Dr. Feng was elected as Fellow of American Association for the Advancement of Science (AAAS).



Wen-Yi Wei
魏文毅
Harvard Medical School

Dr. **Wen-Yi Wei** received his B.A. degree from Shandong University in 1993 and then obtained his M.S. training in Chinese Academy of Science from 1993 to 1996. Afterwards, Dr. Wei received his Ph.D. training in the MCB department at Brown University and his postdoctoral training in the laboratory of Dr. William Kaelin, Jr. at DFCI, Harvard Medical School. Dr. Wei became independent from 2006 in Department Pathology at Beth Israel Deaconess Medical Center, Harvard Medical School. The major focus of the WEI laboratory is aimed at understanding how aberrant cell signaling events contribute to cell cycle dysregulation and subsequent tumorigenesis, which will offer the molecular basis and the rationale to develop novel anti-cancer therapies targeting specific cell signaling pathways.



Jin-Dan Yu
俞锦丹
Northwestern University
Feinberg School of
Medicine

Dr. **Jin-Dan Yu** is currently a Professor of Medicine – Hematology/Oncology and Professor of Biochemistry and Molecular Genetics at the Northwestern University, Feinberg School of Medicine. Dr. Yu received a Bachelor of Medicine degree from Beijing Medical University (Peking University, Health Science Center) in 1998 and a Ph.D. degree in Biomedical Engineering from the University of Michigan – Ann Arbor in 2004. After completing postdoctoral training with HHMI (Howard Hughes Medical Institute) investigator Dr. Arul M. Chinnaiyan at the University of Michigan, Dr. Yu was recruited to join the faculty at Northwestern University Medical School in 2009, wherein she rapidly rose to the rank of Full Professor with Tenure in 2017. Dr. Yu is internationally recognized for her work on genomic and epigenomic regulations of prostate cancer, with strong focuses on androgen receptor (AR), FOXA1, and the Polycomb Group protein EZH2. Her research utilizes integrative genomics and bioinformatics approaches to understand the molecular mechanisms underlying prostate tumorigenesis. Dr. Yu has a strong interest in translating research from the bench to the bedside through the development of novel biomarkers for aggressive prostate cancer and of new treatment regimens for end-stage castration-resistant prostate cancer. Aligned with this, she is a Co-Director of the Translational Bridge Program at the Robert H. Lurie Comprehensive Cancer Center, supervising funding and awards for translational cancer projects. To date, Dr. Yu has published more than 60 peer-reviewed articles, a majority of which in Cell, Science, Nature, and AACR journals. Dr. Yu is an Associate Editor of Oncogene (IF 8.5), is on the Editorial Board of many other journals, and frequently reviews for prestigious journals such as Cancer Cell, Nature Genetics, Genome Research, Nature Communications, and Cancer Research. Dr. Yu has served on many NIH study sections, DOD review panels and review groups for other funding agencies nationally and internationally. Notably, she is currently a Standing Member of the NIH Cancer Etiology (CE) Study Section with her tenure starting in October 2018. Dr. Yu is passionate about the training of the next-generation scientists and has thus far trained 19 postdocs/fellows, 11 graduate students, and 11 undergraduate students in her own laboratory, and served on 19 PhD thesis committees. Dr. Yu is the Director of Ph.D. Training in Cancer Biology Cluster at Northwestern University Graduate School and was recently named the Assistant Director of Education and Training in the Robert H. Lurie Cancer Center. Dr. Yu has received several prestigious awards including the NIH K99/R00 Pathway to Independence Award, the Agilent Early-Career Professor Award, the DOD Impact Award, and the Prostate Cancer Foundation Challenge Award.



Burton B Yang
杨柏华
University of Toronto

Dr. Burton B Yang finished his M.Sc. studies at the South China Agricultural University early 1985. He entered the Ph.D. program at the University of Manitoba in 1988 and received his Ph.D. degree in 1992. After two periods of postdoctoral training at the Manitoba Institute of Cell Biology and Harvard Medical School, Dr. Yang took a Scientist position at Sunnybrook Health Sciences Centre in 1995 and became an Assistant Professor at the Department of Laboratory Medicine and Pathobiology, University of Toronto. He was promoted to Associate Professor in 2001 and to Professor in 2007. During the past 20 years, he received a number of personal awards from the Arthritis Society of Canada, the Premier's Research Excellence Award, Canadian Institutes of Health Research New Investigator Award, CIHR-Ontario Women's Health Council/IGH Mid-Career Award, Career Investigator Award and Investigator Award from the Heart and Stroke Foundation of Canada. Dr. Yang has published 176 papers. Some of them are in high ranking journals including Nature Cell Biology, European Heart Journal, Cell Research, Nature Communications, PNAS. His papers have received over 12000 citations with an H-Index of 63 by Google Scholar.




Shi-Yong Sun
孙士勇
Emory University

Shi-Yong Sun, Ph.D. Department of Hematology and Medical Oncology, Emory Winship Cancer Institute and Emory University School of Medicine, Atlanta, GA, USA. Dr. Sun earned his Ph.D. in cancer pharmacology from Peking Union Medical College (PUMC)/Chinese Academy of Medical Sciences (CAMS) in 1990 and later received his postdoctoral training in cancer biology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, USA. Dr. Sun is currently a tenured Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine and Winship Cancer Institute in Atlanta, Georgia, USA. He is also a Georgia Research Alliance Distinguished Cancer Scientist and Halpern Research Scholar.

Dr. Sun's research primarily focuses on the following areas: 1) regulation of death receptors, particularly TRAIL receptors, by small therapeutic molecules and their implications in drug-induced apoptosis and cancer therapy; 2) understanding mTOR signaling in cancer and targeting the mTOR axis for cancer therapy; and 3) understanding and overcoming acquired resistance to third generation EGFR inhibitors.

Dr. Sun is on the editorial boards of over 30 cancer-related journals and serves as Associate Editors for Molecular Cancer, Molecular Carcinogenesis and BMC Cancer. He has reviewed manuscripts for over 80 scientific journals and grants for over 10 international organizations including different NIH/NCI study sections and has published over 150 original research papers in prominent peer-reviewed journals.



YI LI
李毅
Baylor College of Medicine

Dr. **Yi Li**'s lab investigates the molecular and cellular mechanisms of breast cancer initiation and progression, with the goal of translating this knowledge into breast cancer prevention and treatment. His graduate studies were on molecular biology and microbiology, postdoctoral study under the mentorship of Dr. Harold Varmus provided training in cancer biology and mouse models of breast cancer. Dr. Yi Li's lab has made a number of significant contributions to the field of breast cancer: we pioneered an intraductal retroviral mouse model, RCAS/TVA, to closely recapitulate human breast tumorigenesis, discovered a molecular mechanism underlying the dichotomous effects of pregnancy on breast tumorigenesis, and established intermittent anti-STAT5 treatment for preventing breast cancer in preclinical models, which has resulted in a multi-center window-of opportunity clinical trial (TBCRC042).



Zhen-Kun Lou
楼振昆
Mayo Clinic

Dr. **Zhen-Kun Lou** studies focus on signaling pathways that are activated by DNA damage-inducing agents. DNA damage activates a signaling cascade called DNA damage response (DDR) pathway that initiates DNA repair and cell cycle checkpoint activation. Understanding this pathway will help us understand the cause of genomic instability, a driving force of aging and cancer. Several progeroid genetic syndromes have also been linked to mutations of genes in this pathway, such as Bloom and Warner syndrome. He have been studying the DDR pathway for 18 years and have made unique contributions to the field. His studies help elucidate how DNA damage response factors such as ATM, MDC1, NBS1, 53BP1 and BRCA1 are assembled at the sites of DNA damage and help DNA repair. In addition, through proteomic approaches, they have identified novel factors involved in the DNA damage response downstream of ATM. Recently, his study focuses on the ubiquitination signaling pathway in cell cycle regulation and DNA repair. We have studied several E3 ubiquitin ligases (BRCA1, UHRF1, RNF4, Parkin, WSB1) and deubiquitinases (USP10, USP20, UCHL3) and characterized their role in cell cycle regulation, DNA repair, cellular metabolism and cancer metastasis. He have also studied the regulation of SIRT1, a Sirtuin family deacetylase, by DBC1, and investigated how this regulation affect aging and cancer. Therefore, he have a strong record of successful and productive research projects in a broad area of DNA repair aging and cancer, and his expertise and experience have prepared him to perform the proposed project.



Zhi-Yuan Shen
沈智渊
Rutgers, The State
University of New Jersey

Zhi-Yuan Shen, PhD.

Current Positions (07/2008 – present)


- Professor of Radiation Oncology, Pharmacology
- Chief, Division of Radiation Cancer Biology, Department of Radiation Oncology, Robert Wood Johnson Medical School,
- Co-Leader, Genomic Instability and Cancer Genetics program, NCI designated comprehensive cancer center, Rutgers Cancer Institute of New Jersey, Rutgers The State University of New Jersey

Education and Training

- 02/1994-09/1996: Director's Postdoctoral Fellowship of Los Alamos National Laboratory, Los Alamos, New Mexico, USA
- 01/1990-02/1994: PhD (05/1993) and Postdoc (02/1994), radiation and molecular biology, Dept of Radiological Sciences, Colorado State University, Fort Collins, CO, USA (thesis advisor: Mortimer M. Elkind)
- 08/1985-08/1988: MS (radiation medicine and toxicology), Beijing Institute of Radiation Medicine, Beijing, China.
- 09/1980-08/1985: MD, Norman Bethune University of Medical Sciences (presently Jilin University School of Medicine), Jilin, China

Past Positions

- 05/2006 – 06/2008: Tenured Professor (07/2008-), Tenured Associate Professor (05/2006), inaugural Chief (05/2006 -) of Division of Radiation Cancer Biology at Department of Radiation Oncology, and Co-leader (12/2008-) of Genomic Instability and Cancer Genetics program, NCI Designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey. Rutgers University
- 05/2000 - 05/2006: Tenured Associate professor (07/2003-05/2006), Tenure-track Assistant Professor (2000-2003), and Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM
- 05/1997 - 05/2000: Tenure-track Assistant Professor, Cancer Center and Department of Molecular Genetics, University of Illinois at Chicago, Chicago, IL.
- 09/2016 – 05/1997: Staff Scientist, Los Alamos National Laboratory, New Mexico, USA



Chu-Xia Deng
邓初夏
University of Macau

Professor **Chu-Xia Deng** obtained his master degree of science in the Institute of Hydrobiology, Chinese Academia of Science in 1984 and Ph.D degree in the Department of Biology, University of Utah in 1992, respectively. As a PhD student, Deng studied with professor Mario R. Capecchi, a co-winner of the Nobel Prize in Physiology or Medicine in 2007. After finishing his postdoctoral training in the Harvard Medical School in 1995, he became a Tenure-Track Investigator, then the Tenured-Investigator and the Chief of the Mammalian Genetics Section at the United States National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of National Institutes of Health (NIH). His current position is the Dean of Faculty of Health Sciences, University of Macau.

Over the past two decades, the research team led by Professor Deng has made Significant contributions to research on cancer and metabolic diseases, ageing, cancer stem cells, particularly in the underlying mechanisms for BRCA1 associated breast cancer. These data have attained important results that have attracted worldwide attention. He and his team have published over 370 papers including over 40 in Cell, Nature, Science and their sister journals, with a total citation of >57,000 times and a H-index of 128 by Google Scholar.

Professor Deng received the NIH-APAO Outstanding Achievement Award (2000, NIH, USA), Outstanding Oversea Scholar from National Science Foundation (2002, China), NIDDK "You Make A Difference Award" (2005, 2013), and NIDDK Director's Award (2011). He was elected as a Fellow of the American Association for the Advancement of Sciences (AAAS) in 2012.

主持人简介 (排序按递交先后)



Wen-Hui Li
李文辉
云南省肿瘤医院/昆明医科
大学第三附属医院

李文辉，医学博士，二级教授，博导。
云南省肿瘤医院/昆明医科大学第三附属医院 副院长
云南省肿瘤放射治疗研究中心 主任
国务院特殊津贴专家，云岭名医
云南省突出贡献优秀专业技术人才
美国（芝加哥）伊州大学癌症中心博士后研究员

中华医学会放射肿瘤治疗学分会常委，中国医师协会肿瘤放射治疗分会常委，中国抗癌协会肿瘤放射治疗专委会委员，西部放射治疗协会副理事长。

4省专委会第一届主任委员（省医学会放射肿瘤治疗学分会、医师协会肿瘤放射治疗分会、抗癌协会肿瘤放射治疗专委会、省医院协会肿瘤专委会）。

主持国家自然科学基金2项，国家重点研发计划子课题1项，省国际合作重点项目1项，省厅级项目20项。获云南省科技进步三等奖2项。发表论文150余篇，SCI收录29篇(IF>80)，编写专著8部。



Bao-Wei Jiao
焦保卫
中科院昆明动物所

焦保卫。2000年获得西南大学生命科学院理学学士；2007年在香港中文大学获博士学位，2008-2013年在美国马萨诸塞大学医学院作博士后研究，2013年到中科院昆明动物所任学科组长、研究员、博导。中科院“动物进化与遗传前沿交叉卓越中心”骨干，遗传资源与进化国家重点实验室副主任。在Cell、PNAS等杂志发表论文20余篇。入选“青年千人计划”、“云南省海外高层次人才”和“云南省高端科技人才”。目前从表观遗传角度研究乳腺干细胞及乳腺癌干细胞的调控作用。受到多个人才项目资助及主持多个干细胞相关科研项目：中组部青年千人计划、国家自然科学基金面上项目、云南省高端科技人才项目、中科院先导项目课题，科技部“干细胞与转化研究”重点研发计划、基金委-云南省联合重点项目等。任中国细胞生物学会理事等学术兼职。


代表性论文：

1. Ke H#, Zhao L#, Zhang H#, Feng X, Xu H, Hao J, Wang S, Yang Q, Zou L, Su X, Wang L, Wu C, Wang Y, Nie J, Jiao B*, 2018. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3. Proc Natl Acad Sci U S A. 115(15):E3426-E3435.
2. Wang S#, Ke H#, Zhang H, Ma Y, Ao L, Zou L, Yang Q, Zhu H, Nie J*, Wu C*, Jiao B*. 2018. LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci. Cell Death Dis. 24;9(8):805. doi: 10.1038/s41419-018-0869-2.
3. Jiao B, Ma H, Shokhirev M, Drung A, Yang Q, Shin J, Lu S, Byron M, Kalantry S, Mercurio AM, Lawrence JB, Hoffmann A. and Bach I. 2012. Paternal RLIM/Rnf12 is a survival factor for milk-producing alveolar cells. Cell. 149:630-41.



Wen Liu
刘文
厦门大学

刘文，中组部“青年千人计划”、“闽江学者”特聘教授、博士生导师。2001年毕业于厦门大学生物学系，获生物学学士学位；2002年至2005年工作于美国Sanford-Burnham医学研究所；2011年毕业于美国加州大学圣地亚哥分校生物学系，获生物学博士学位；2011年至2013年工作于美国加州大学圣地亚哥分校医学院；现任厦门大学药学院教授。主要从事表观遗传调控子（组蛋白修饰酶、去修饰酶、识别修饰的识别子、非编码RNA）在基因转录和剪接调控中的作用分子机制研究，及其在癌症等重大疾病发生发展中的应用研究；同时也致力于探寻靶向表观遗传调控子的活性小分子。研究获得国家自然科学基金（重大研究计划（培育项目）；国际(中美)合作与交流项目；优秀青年科学基金项目；面上项目）以及福建省自然科学基金（杰出青年科学基金项目）等项目的支持。论文发表在Nature, Cell, Cancer Cell, Molecular Cell, PNAS等科学期刊。取得多项荣誉，获得中国药学会-赛诺菲青年生物药物奖和福建省运盛青年科技奖。



Cai-Xia Guo
郭彩霞
中科院北京基因组研究所

郭彩霞，1991年获得武汉大学生命科学院理学学士；1999年于中科院动物研究所获得博士学位；1999-2004年先后在美国肯塔基大学和西南医学中心从事博士后研究；2004-2009年先后在美国西南医学研究中心担任讲师和研究助理教授，2009年入选中科院“百人计划”，受聘为中科院北京基因组研究所研究员、博士生导师。科研方向主要是DNA损伤应答、基因组不稳定性与疾病相关性研究。目前已在Cell、Molecular Cell、PNAS、Nature Communication等期刊发表多篇学术论文，承担多项国家自然科学基金等。



Tie-Bang Kang
康铁邦
中山大学肿瘤防治中心

康铁邦个人简介：博士、教授、博士生导师，教育部“长江学者”特聘教授（2015.01--2019.12），国家杰出青年科学基金获得者（2011年）。现任中山大学肿瘤防治中心实验研究部副主任，华南肿瘤学国家重点实验室PI，中国细胞生物学学会肿瘤细胞生物学分会副会长，中国抗癌协会肿瘤病因专业委员会副主任委员。2003年，获德国Bielefeld大学生物化学博士学位。1998--2008年，一直在美国、德国从事细胞生物学、肿瘤学研究工作。2008年5月，全职回国（中山大学“百人计划”引进人才）。已获得国家自然科学基金重点项目2项、“973”计划项目（2项）、国家肝癌重大专项基金（1项）、国家重点研发计划（2项）。通讯或第一作者在Cancer Cell, J Clin Invest, Cell Res, J Natl Cancer Inst, Nucleic Acids Res, Cancer Res, Clin Cancer Res, Oncogene, J Pathol, J Biol Chem 等国际主流杂志上发表论著40篇。研究方向：肿瘤转移的调控、肿瘤耐药的机制与干预等



Mu-Sheng Zeng
曾木圣
中山大学肿瘤防治中心

曾木圣教授 中山大学肿瘤防治中心

个人简介：现任中山大学肿瘤防治中心副主任、副院长，华南肿瘤学国家重点实验室肿瘤病毒与生物标记研究室PI。兼任中国抗癌协会肿瘤标志专业委员会副主任委员，广东省抗癌协会秘书长，当选2022鼻咽癌 Gordon Research Conference大会主席。1988年毕业于江西医学院抚州分院，1994年获中山医科大学肿瘤学硕士学位，1998年获中山医科大学微生物学博士学位，1999年至2003年分别在美国田纳西州立大学和新英格兰医学中心（Tufts-New England Medical Center）从事博士后研究。2010年获国家杰出青年科学基金资助，2014年教育部长江学者特聘教授，2016年广东省“南粤百杰”。主要从事恶性肿瘤病因、发病机制及肿瘤标志研究，主持国家重点研发计划蛋白质专项（首席）、国自然重点及重大国合等国家级项目多项，建立体外上皮细胞EB病毒高效感染模型，鉴定EB病毒感染上皮细胞受体及共受体、并阐明相关感染机制。以通讯或共同通讯作者在国际上主流期刊Nat Microbiol, Cancer Cell, Nat Commun (3), PNAS, J Clin Invest, JNCI (2), PLoS Pathog, Cancer Res, Clin Cancer Res, JBC等发表SCI收录论文40多篇。



Hai-Zhong Feng
冯海忠
上海交通大学

Dr. Haizhong Feng is currently a Professor of State Key Laboratory of Oncogenes and Related Genes & Clinical Stem Cell Research Center at Renji Hospital, Shanghai Jiao Tong University School of Medicine. Dr. Feng received his PhD degree from Institute of Genetics and Developmental Biology, Chinese Academy of Sciences in China in 2007, and then received his postdoctoral training in Texas Tech University and University of Pittsburgh Medical School in USA from 2006 to 2012. From 2012 to 2013, Dr. Feng was a Research Assistant Professor of Neurology at Northwestern University. In 2013, Dr. Feng joined faculty at Renji Hospital, Shanghai Jiao Tong University School of Medicine as a Principal Investigator. Dr. Feng was honored as a Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, an outstanding Academic Leader (New Hundred Talent) at Shanghai Municipal Health Bureau, a Two-Hundred Talent at School of Medicine, Shanghai Jiao Tong University.

Dr. Feng's research interests are to study cancer metastasis and cancer stem cells regulated by protein modification-related oncogenic signalings, non-coding RNAs, and epigenetic modification, and develop novel therapeutic approaches for treating human solid tumors. Dr. Feng has published 28 peer-reviewed papers in top-ranked biomedical journals as first, senior or co-author including JCI, Nature Communications, PNAS, and Cancer Res. Dr. Feng is an expert reviewer for Israel Science Foundation and other foundations. Dr. Feng's research has been continuously supported by grants from the China NSF and state governments. Dr. Feng is a regular reviewer for Oncogene, Cancer Letters, J Neuro-Oncology, et al.